BCL2 is a gene that encodes a protein that helps keep cells alive. In healthy tissue, this is a carefully controlled process — BCL2 helps specific cells survive longer when needed, but the signal can be switched off when those cells are no longer required. In some cancers, particularly lymphomas and certain blood cancers, the BCL2 protein becomes permanently overactive, blocking a normal cell death process called apoptosis. When cancer cells cannot die, they accumulate, and the tumour grows. Because of this central role, BCL2 is both a diagnostic marker — helping identify the type of cancer — and a treatment target, since drugs can directly block the BCL2 protein.
How does BCL2 become overactive in cancer?
In the most common scenario, BCL2 becomes overactive because of a gene rearrangement called t(14;18). This happens when a segment of chromosome 14 and a segment of chromosome 18 break off and swap places. The swap puts the BCL2 gene right next to a stretch of DNA that is permanently switched on in B cells — the immune cells where lymphomas begin. Under the control of this new neighbor, BCL2 is produced constantly and in large amounts. The cell becomes resistant to the normal signals that would tell it to die. This t(14;18) rearrangement is the hallmark of follicular lymphoma and is also found in a significant proportion of diffuse large B-cell lymphomas.
In other cancers, BCL2 can become overactive through gene amplification (extra copies of the gene) or other molecular changes, without a rearrangement.
Which cancers are commonly associated with BCL2?
Abnormal BCL2 activity is most common in lymphomas and other blood cancers:
- Follicular lymphoma — the t(14;18) rearrangement and BCL2 overexpression are a defining feature of this cancer. BCL2 positivity helps distinguish follicular lymphoma from benign (non-cancerous) reactive changes in lymph nodes, where BCL2 is typically absent from the follicle centers.
- Diffuse large B-cell lymphoma (DLBCL) — BCL2 expression is common and is an important prognostic marker. When the BCL2 protein is strongly expressed alongside the MYC protein, the lymphoma may be classified as a double expressor, which is associated with a more aggressive course.
- High-grade B-cell lymphoma with MYC and BCL2 rearrangements — when both the BCL2 and MYC genes show rearrangements, the lymphoma is classified as a double-hit lymphoma. These are highly aggressive tumors that require intensive treatment.
- Chronic lymphocytic leukemia (CLL) — BCL2 is overexpressed in virtually all CLL cases and is the primary target of the drug venetoclax (see below).
BCL2 abnormalities are also found in mantle cell lymphoma, some multiple myeloma cases, and a small number of solid tumors, though the clinical significance varies by cancer type.
Why do pathologists test for BCL2?
BCL2 testing serves several purposes:
- Diagnosis and classification. BCL2 positivity in follicle centers helps confirm a diagnosis of follicular lymphoma. Combined with other markers, it helps classify aggressive lymphomas and identify double-hit or double-expressor subtypes.
- Prognosis. Strong BCL2 expression in DLBCL, especially alongside MYC, is associated with a more aggressive tumour and a higher risk of treatment failure with standard chemotherapy.
- Treatment eligibility. BCL2 is a direct target of the drug venetoclax (Venclexta), which works by blocking BCL2 and restoring the cancer cell’s ability to die. Venetoclax is approved for CLL and certain other blood cancers, and BCL2 expression guides decisions about its use.
How is BCL2 tested?
BCL2 can be tested using several laboratory methods, often used in combination:
- Immunohistochemistry (IHC) — detects the BCL2 protein directly in tumour tissue and shows whether it is present at high levels. This is usually the first test performed.
- FISH (fluorescence in situ hybridization) — looks for the t(14;18) rearrangement or other BCL2 gene rearrangements at the DNA level. Used when IHC results need confirmation or when genetic classification is required.
- Next-generation sequencing (NGS) can detect mutations or rearrangements involving BCL2 as part of a broader molecular panel.
How results are reported
BCL2 results typically appear in the immunohistochemistry, molecular testing, or biomarker sections of a pathology report. Common phrasings include:
- BCL2 positive — the BCL2 protein is present at elevated levels in the tumour cells.
- BCL2 negative — little or no BCL2 protein is detected.
- BCL2 rearrangement detected — FISH has identified a gene rearrangement involving BCL2.
- No BCL2 rearrangement detected — no gene rearrangement was found on FISH testing.
BCL2 results are almost always interpreted alongside other markers — particularly MYC, BCL6, CD20, and Ki-67 — rather than on their own. The combination of results determines the type and grade of lymphoma and guides treatment planning.
Questions to ask your doctor
- Was my tumour tested for BCL2, and what did the result show?
- Does my BCL2 result affect how my lymphoma is classified or how aggressive it is likely to be?
- Am I eligible for venetoclax or another BCL2-targeting treatment?
- Were MYC and BCL6 also tested, and what do those results mean together with my BCL2 result?
Related articles on MyPathologyReport.com